Immune Pharmaceuticals Inc

Immune Pharmaceuticals — Investor Presentation (October 2014)

25 slides from Immune Pharmaceuticals's investor presentation, Oct 8, 2014

  1. Slide 1: Corporate Presentation

    CORPORATE PRESENTATION Dr. Daniel Teper, Chairman and Chief Executive Officer October 2014

  2. Slide 2: Forward-Looking Statement

    Forward - Looking Statement This presentation contains forward looking statements that involve risks and uncertainties regarding the operations and future results of Immune. You should review Immune ’ s filings with the Securities and Exchange Commission, including without limitation the company's F

  3. Slide 3: Corporate

    Corporate

  4. Slide 4: Investment Highlights

    Investment Highlights NASDAQ listed company with First in Class Clinical Stage Biologic candidate - Bertilimumab - for Auto - Immune Diseases ▪ Novel, Highly Targeted Personalized Antibody Therapeutic with Companion Diagnostic opportunity ▪ Currently in Phase 2 for Bullous Pemphigoid (BP), an Orphan

  5. Slide 5: Clinical Stage Portfolio With Multiple Shots on Goal

    Clinical Stage Portfolio With Multiple Shots on Goal Resources Prioritized For Bertilimumab Phase 2 BP and UC Data Expected in 2014 - 15 Core Programs Preclinical Phase 1 Phase 2 Phase 3 Anticipated Catalyst BERTILIMUMAB Bullous Pemphigoid (Orphan Derm . Disease) Phase 2 data 2015 Ulcerative Colitis

  6. Slide 6: Highly Experienced Management Team and Board

    Highly Experienced Management Team and Board 6 Daniel Teper , PharmD , MBA Founder, Chairman & CEO ; Novartis, GSK, Sanofi , Bionest Eugene Williams, MBA Chief Operating Officer ; Genzyme, Adheris , Bain, Dart Therapeutics Elliot Goldstein, MD Chief Medical Officer ; Novartis, GSK, British Biotech,

  7. Slide 7: Financial Highlights

    Financial Highlights 7 NASDAQ Symbol IMNP Share Price as of September 2, 2014 $3.80 Market Cap as of September 2, 2014 $64.2M Shares Outstanding as of September 2, 2014 16.9M Preferred C Stock 1.6M Warrants (6.90 M in the money ) 7.3M Options (1.89 M in the money) 5.5M Fully Diluted Shares as of Sep

  8. Slide 8: Changing the outcome of inflammatory diseases through better patient selection

    Changing the outcc flammatory diseases through bi patient selection OF MMUNE

  9. Slide 9: Bertilimumab: A New Model for Personalized Medicine and Eotaxin-1 Targeted Therapy

    Bertilimumab: A New Model for Personalized Medicine and Eotaxin - 1 Targeted Therapy in Autoimmune Disease 9 Identify diseases where Eotaxin - 1 plays a significant role Screen patients for high levels of Eotaxin - 1 in disease tissue Treat selected patients with Bertilimumab Personalized targeted t

  10. Slide 10: Bullous Pemphigoid is an Aggressive, Serious Disease

    Bullous Pemphigoid is an Aggressive , Serious Disease and Can Lead to Life Threatening Conditions

  11. Slide 11: Who are BP Patients? What do they risk?

    Who are BP Patients? What do they risk? 11 Rare autoimmune skin blistering disorder Estimated 30 , 000 patients in North America and Europe combined, similar in size to Duchenne Muscular Dystrophy and Cystic Fibrosis BP is most common in people over the age of 60 , more common in women Patients are

  12. Slide 12: Why Steroids do not address the needs of BP patients

    Why Steroids do not address the needs of BP patients 12 Initial Control of the disease requires very high daily dose of oral steroids ( 1 mg/kg or around 60 mg prednisone) and high potency topical steroids Long - Term Control requires chronic use of high dose systemic steroids 75 % of Patients suffe

  13. Slide 13: Eosinophils are Predominant in the BP Inflammatory Process

    Eosinophils are Predominant in the BP Inflammatory Process Bertilimumab Neutralizes Eotaxin - 1 , a Key Regulator of Eosinophils 13 Significant unmet need for targeted therapy with improved safety profile SOURCE: Dr. Neil Kormin , Case Western

  14. Slide 14: Bertilimumab Binds Specifically to Eotaxin-1

    Bertilimumab Binds Specifically to Eotaxin - 1 and reduces eotaxin - 1 mediated Dermal I nflammation Comparative effect of CAT - 213 to neutralize eotaxin 1 from human,  monkey, rat, and mouse IC 50 95 % confidence interval (CI) for inhibition of eotaxin 1 ( 6 nM ) - induced chemotaxis of L 1 . 2 -

  15. Slide 15: Bertilimumab Phase 2 Proof of Concept Trial in BP

    15 Bertilimumab Phase 2 Proof of Concept Trial in BP Ongoing Phase 2 ▪ Open - label single arm study ▪ 10 - 15 newly diagnosed moderate to severely extensive BP patients ▪ Drug administration of 10mg/kg (30 min. IV infusion) on days 0 and 14, follow - up until day 60 ▪ Initial data expected 2014/ear

  16. Slide 16: Bertilimumab in BP is IMNP Lead Program

    Bertilimumab in BP is IMNP Lead Program with Phase II POC Data expected in coming months Goal: to dramatically reduce the use of steroids while achieving disease control and remission ▪ In both the initial induction phase and in long term maintenance therapy to reduce mortality risk and patient morb

  17. Slide 17: Landmark Nature Publications Highlight Key Role of Eotaxin

    Landmark Nature Publications H ighlight Key role of Eotaxin in Respiratory & GI Inflammation 17 Luster & all Nature Medicine Vol 2 Number 4 1996 Rothenberg & all Nature Immunology Vol 2 Number 4 2001

  18. Slide 18: Vanderbilt-NIH Clinical Study establishes Eotaxin-1 as Biomarker and Therapeutic Target in UC

    Vanderbilt - NIH Clinical Study establishes Eotaxin - 1 as a Biomarker and Therapeutic Target in Ulcerative Colitis 18 Tissue eotaxin - 1 significantly increased in more severe patients (based on Mayo Clinic Disease Activity Index, mucosal injury and Histology severity) Increased eotaxin - 1 correla

  19. Slide 19: Bertilimumab Proof-of-Concept Phase II Trial in Ulcerative Colitis

    Bertilimumab Proof - of - Concept Phase II Trial in Ulcerative Colitis Target Labeling ahead of Anti - TNFs in Moderate to Severe UC with Patient Selection based on Tissue Eotaxin 1 levels (Companion Diagnostic) 19 Trial Design ▪ Double - blind placebo controlled trial in 42 patients with moderate t

  20. Slide 20: Exclusivity and Intellectual Property

    Exclusivity and Intellectual Property 20 Biologics have 12 year marketing exclusivity in the US, 10 years in Europe BP is an Orphan Disease – a grant of Orphan Designation confers 7 years of market exclusivity in the US, and 10 years in the EU Immune has filed use IP in IBD (including UC) in 2013 an

  21. Slide 21: Bertilimumab: Origins, Manufacturing Process and Patient Foundation Support

    Bertilimumab: Cambridge Antibody Technology Origins, Manufacturing Process and Patient Foundation Support 21 Bertilimumab was discovered by Cambridge Antibody Technology (CAT) using their phage display technology Manufactured by Lonza - an industry leader in biologics manufacturing International Pem

  22. Slide 22: Late-stage product, neuropathic pain

    Late-stage product, neuropathic pain ensing in OF MMUNE

  23. Slide 23: AmiKet: A Significant Short Term Monetization Opportunity

    AmiKet : A Significant Short Term Monetization Opportunity Advanced Partnering Discussions On Going • Significant late stage product opportunity in large and growing neuropathic pain market ($ 5 B) with high unmet medical need; Focused physician audience (Pain Specialists and Neurologists); limited

  24. Slide 24: AmiKet Non-Inferior to Gabapentin HD in Post Herpetic Neuralgia

    AmiKet Non - Inferior to Gabapentin HD in Post Herpetic Neuralgia 24 Met primary endpoint: ▪ Efficacy superior to placebo, p =. 044 ▪ Not inferior to gabapentin, p =. 84 Results indicate non inferior efficacy to market leader and excellent side effect profile Primary Endpoint: Mean Pain Score AmiKet

  25. Slide 25: Investment Highlights

    Investment Highlights NASDAQ listed company with First in Class Clinical Stage Biologic candidate - Bertilimumab - for Auto - Immune Diseases ▪ Novel , Highly Targeted Personalized Antibody Therapeutic with Companion Diagnostic opportunity ▪ Currently in Phase 2 for Bullous Pemphigoid (BP), an Orpha

Immune Pharmaceuticals — Investor Presentation (October 2014) on 6ix